Search

everythinglearnresearchcommunity

for

Search:↓

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

Stemson raised $15M for hair cloning, with hopes it becomes a reality in 10-20 years. Users are hopeful and discuss using Minoxidil and finasteride in the meantime.

The user is experiencing hair loss and is using oral treatments including 5mg minoxidil, 1.1mg finasteride, and 1mg biotin daily. They are considering adding dutasteride and possibly a hair system, while others suggest patience and additional treatments like microneedling.

The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

The user reports significant hair regrowth after 5 months using oral finasteride and minoxidil. They seek advice on restarting treatment and using derma rollers after a 2-month break.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The user experienced hair regrowth and improved hair density using oral finasteride and topical minoxidil, with microneedling as an additional treatment. They are considering a hair transplant for low-density areas but are uncertain due to existing follicles.

The user reported solid results after 5 months of using 1.25mg finasteride daily, with minimal sexual side effects and some hair regrowth at the hairline. They discontinued minoxidil due to its greasy effect on their hair.

People are excited about a new hair loss treatment, PP405, and some suggest using Twitter to increase its visibility. Current treatments mentioned include finasteride, minoxidil, and dutasteride, but skepticism remains about the effectiveness of new treatments.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

User shared 4.5-month hair loss treatment results using Fin, Minoxidil, and microneedling. Others discussed postponing hair transplant and adjusting microneedling depth.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The conversation discusses the anticipated release of GT20029, with some users expressing skepticism about its availability. It also mentions the use of treatments like Minoxidil, finasteride, RU58841, and dutasteride for hair loss.

Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.

A user reported significant hair regrowth after 3 months using 1mg oral finasteride, 1ml 5% topical minoxidil, and microneedling, along with biotin, vitamin D, iron, and zinc supplements. They are optimistic about continued progress despite initial skepticism.

A user shared their positive experience with a hair transplant at Wimpole Clinic, performed by Dr. Malkani, and discussed using finasteride at a reduced dose due to side effects. They also mentioned avoiding minoxidil due to heart pain and taking supplements like biotin, marine collagen, viviscal, and krill oil.

A user shared progress pictures after 5 months of using oral Minoxidil (2.5mg) and Finasteride (1mg) for hair loss, reporting satisfaction with the results despite some light spots. Another user suggested increasing the Minoxidil dose if needed after a year.

User shared 1.5-year progress using 1mg finasteride, 15% minoxidil daily, and derma rolling weekly. Experienced initial shedding but achieved significant hair regrowth and improvement.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

RU58841 is used without finasteride by some due to side effects, with mixed results. Users report combining RU58841 with minoxidil and adjusting finasteride doses to manage hair loss.

Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.

The user reports significant hair regrowth using finasteride, topical minoxidil, and dermarolling twice a week, despite poor photo quality. Another user shares their experience with oral minoxidil and finasteride, noting ongoing shedding and considering additional treatments.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

A 30-year-old male has been experiencing hair loss despite using Dutasteride 0.5mg and PRP for 15 months, with no success. He is considering a hair transplant but is advised to stabilize hair loss first and explore other treatments like topical Minoxidil or combined therapies.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.